Endologix (ELGX) 10-Q 5 Aug 15 2015 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Jul. 31, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	ENDOLOGIX INC /DE/
Entity Central Index Key	1,013,606
Document Type	10-Q
Document Period End Date	Jun. 30, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		67,781,092
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands		Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents		$ 36,269	$ 26,798
Marketable securities		34,257	59,871
Accounts receivable, net allowance for doubtful accounts of $181 and $185, respectively.		29,138	26,113
Other receivables		121	498
Inventories		30,588	31,325
Prepaid expenses and other current assets		2,592	3,162
Total current assets		132,965	147,767
Property and equipment, net		24,808	25,696
Goodwill	[1]	28,709	28,866
Intangibles, net		42,702	43,465
Deposits and other assets		2,138	2,415
Total assets		231,322	248,209
Current liabilities:
Accounts payable		11,760	11,027
Accrued payroll		11,469	13,337
Accrued expenses and other current liabilities		4,979	5,260
Total current liabilities		28,208	29,624
Deferred income tax		879	879
Deferred rent		8,078	8,060
Other liabilities		349	489
Contingently issuable common stock		14,800	14,600
Convertible notes		72,156	70,407
Total liabilities		$ 124,470	$ 124,059
Commitments and contingencies
Stockholders’ equity:
Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized. No shares issued and outstanding.		$ 0	$ 0
Common stock, $0.001 par value; 100,000,000 shares authorized. 67,947,684 and 67,321,769 shares issued, respectively. 67,767,730 and 67,159,511 shares outstanding, respectively.		68	67
Treasury stock, at cost, 179,954 and 162,258 shares, respectively.		(2,619)	(2,328)
Additional paid-in capital		381,516	372,639
Accumulated deficit		(272,715)	(248,500)
Accumulated other comprehensive income		602	2,272
Total stockholders’ equity		106,852	124,150
Total liabilities and stockholders’ equity		$ 231,322	$ 248,209
[1]	Difference in the value between these dates is solely due to a foreign currency translation adjustment.

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Allowance for doubtful accounts	$ 181	$ 185
Common stock, par value (per share)	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	67,947,684	67,321,769
Common stock, shares outstanding	67,767,730	67,159,511
Treasury stock, shares	179,954,000	162,258,000
Convertible Preferred Stock
Convertible preferred stock, par value (per share)	$ 0.001	$ 0.001
Convertible preferred stock, shares authorized	5,000,000	5,000,000
Convertible preferred stock, shares issued	0	0
Convertible preferred stock, shares outstanding	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
Revenue	$ 39,479	$ 38,327	$ 76,149	$ 71,591
Cost of goods sold	15,347	9,820	25,111	18,789
Gross profit	24,132	28,507	51,038	52,802
Operating expenses:
Research and development	5,993	4,458	12,224	8,563
Clinical and regulatory affairs	3,597	2,722	7,047	4,922
Marketing and sales	19,842	19,167	39,441	35,311
General and administrative	6,850	5,932	14,139	13,094
Total operating expenses	36,282	32,279	72,851	61,890
Loss from operations	(12,150)	(3,772)	(21,813)	(9,088)
Other income (expense):
Interest income	37	67	82	126
Interest expense	(1,493)	(1,448)	(2,955)	(2,839)
Other income (expense), net	766	(148)	824	211
Change in fair value of contingent consideration related to acquisition	(100)	(3,772)	(200)	8,028
Total other income (expense)	(790)	(5,301)	(2,249)	5,526
Net loss before income tax (expense) benefit	(12,940)	(9,073)	(24,062)	(3,562)
Income tax (expense) benefit	(61)	80	(153)	(136)
Net loss	(13,001)	(8,993)	(24,215)	(3,698)
Other comprehensive income (loss) foreign currency translation	84	68	(1,670)	23
Comprehensive loss	$ (12,917)	$ (8,925)	$ (25,885)	$ (3,675)
Basic and diluted net loss per share	$ (0.19)	$ (0.14)	$ (0.36)	$ (0.06)
Shares used in computing basic and diluted net loss per share	67,615	62,699	67,441	62,403

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities:
Net loss	$ (24,215)	$ (3,698)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,933	1,213
Stock-based compensation	4,619	3,753
Change in fair value of contingent consideration related to acquisition	200	(8,028)
Accretion of interest on convertible note	1,749	1,622
Amortization of deferred financing costs	232	198
Non-cash foreign exchange gain	(655)	(212)
Changes in operating assets and liabilities:
Accounts receivable and other receivables	(3,195)	(2,108)
Inventories	739	(8,793)
Prepaid expenses and other current assets	413	(1,283)
Accounts payable	2,692	3,855
Accrued payroll	(1,689)	1,224
Accrued expenses and other liabilities	(207)	2,097
Net cash used in operating activities	(16,384)	(10,160)
Cash flows from investing activities:
Purchases of marketable securities	(37,122)	(74,114)
Maturities of marketable securities	62,690	25,585
Purchases of property and equipment	(3,146)	(5,743)
Net cash provided by (used in) investing activities	22,422	(54,272)
Cash flows from financing activities:
Proceeds from sale of common stock under employee stock purchase plan	1,631	1,446
Proceeds from exercise of stock options	2,628	1,094
Minimum tax withholding paid on behalf of employees for restricted stock units	(291)	(1,395)
Net cash provided by financing activities	3,968	1,145
Effect of exchange rate changes on cash and cash equivalents	(535)	(22)
Net increase (decrease) in cash and cash equivalents	9,471	(63,309)
Cash and cash equivalents, beginning of period	26,798	95,152
Cash and cash equivalents, end of period	36,269	31,843
Supplemental disclosure of cash flow information:
Cash paid for interest	973	1,045
Cash paid for income taxes	140	207
Non-cash investing and financing activities:
Landlord funded leasehold improvements	46	3,870
Fair value of Nellix Milestone Shares (note 9)	0	38,372
Acquisition of property and equipment included in accounts payable	$ 71	$ 1,403

Description of Business, Basis

Description of Business, Basis of Presentation, and Operating Segment	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business, Basis of Presentation, and Operating Segment	Description of Business, Basis of Presentation, and Operating Segment (a) Description of Business Endologix, Inc. (the "Company") is a Delaware corporation with corporate headquarters and production facilities located in Irvine, California. The Company develops, manufactures, markets, and sells innovative medical devices for the treatment of aortic disorders. The Company's products are intended for the minimally invasive endovascular treatment of abdominal aortic aneurysms ("AAA"). The Company's AAA products are built on one of two platforms: (1) traditional minimally-invasive endovascular repair ("EVAR") or (2) endovascular sealing (“EVAS”), the Company's innovative solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The Company's current EVAR products include the Endologix AFX Endovascular AAA System (“AFX”), the VELA Proximal Endograft (“VELA”) and the Endologix Intuitrak Endovascular AAA System (“Intuitrak”). The Company's current EVAS product is the Nellix Endovascular Aneurysm Sealing System (“Nellix EVAS System”). Sales of the Company's EVAR and EVAS platforms (including extensions and accessories) to hospitals in the U.S. and Europe, and to third-party international distributors, provide the sole source of the Company's reported revenue. The Company's EVAR products consist of (i) a cobalt chromium alloy stent covered by polytetrafluoroethylene (commonly referred to as "ePTFE") graft material (“Stent Graft”) and (ii) an accompanying delivery system. Once fixed in its proper position within the abdominal aorta, the Company's EVAR device provides a conduit for blood flow, thereby relieving pressure within the weakened or “aneurysmal” section of the vessel wall, which greatly reduces the potential for the AAA to rupture. The Company's EVAS product consists of (i) bilateral covered stents with endobags, (ii) a biocompatible polymer injected into the endobags to seal the aneurysm and (iii) a delivery system and polymer dispenser. The Company's EVAS product seals the entire aneurysm sac effectively excluding the aneurysm sac reducing the likelihood of future aneurysm rupture. Additionally, it has the potential to reduce post procedural re-interventions. (b) Basis of Presentation The accompanying Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") and the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). These financial statements include the financial position, results of operations, and cash flows of the Company, including its subsidiaries, all of which are wholly-owned. All inter-company accounts and transactions have been eliminated in consolidation. For the three and six months ended June 30, 2015 and 2014, there were no related party transactions. The interim financial data as of June 30, 2015 is unaudited and is not necessarily indicative of the results for a full year. In the opinion of the Company's management, the interim data includes normal and recurring adjustments necessary for a fair presentation of the Company's financial results for the three and six months ended June 30, 2015 . Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to SEC rules and regulations relating to interim financial statements. The accompanying Condensed Consolidated Financial Statements should be read in conjunction with the Company's audited Consolidated Financial Statements and Notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2014 , filed with the SEC on March 2, 2015. On May 28, 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU ") No. 2014-09, "Revenue from Contracts with Customers", which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The FASB agreed to a one-year deferral of the revenue recognition standard's effective date for all entities. The new standard is effective for the Company on January 1, 2018. The standard permits the use of either the retrospective or cumulative effect transition method. Early application is permitted, but not before the original effective date, which would have been January 1, 2017 for the Company. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting. On April 7, 2015, the FASB issued ASU No. 2015-03, "Simplifying the Presentation of Debt Issuance Costs", which requires debt issuance costs related to a recognized debt liability to be presented on the balance sheet as a direct deduction from the debt liability, similar to the presentation of debt discounts. The ASU is effective for the Company on January 1, 2016. Early adoption is permitted. The Company is evaluating the effect that ASU 2015-03 will have on its consolidated financial statements and related disclosures. On July 22, 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory,” which requires an entity to measure inventory within the scope of the amendment at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company is currently assessing the impact this guidance will have on its consolidated financial statements. (c) Operating Segment The Company has one operating and reporting segment that is focused exclusively on the development, manufacture, marketing, and sale of EVAR and EVAS product for the treatment of aortic disorders. For the three and six months ended June 30, 2015 , all of the Company's revenue and related expenses were solely attributable to these activities. Substantially all of the Company's long-lived assets are located in the U.S.

Use of Estimates and Summary of

Use of Estimates and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Use of Estimates and Summary of Significant Accounting Policies	Use of Estimates and Summary of Significant Accounting Policies The preparation of financial statements in conformity with GAAP requires the Company's management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenue and expenses, and related disclosure of contingent liabilities. On an on-going basis, the Company's management evaluates its estimates, including those related to (i) collectibility of customer accounts; (ii) whether the cost of inventories can be recovered; (iii) the value of goodwill and intangible assets; (iv) realization of tax assets and estimates of tax liabilities; (v) likelihood of payment and value of contingent liabilities; and (vi) potential outcome of litigation. Such estimates are based on management's judgment which takes into account historical experience and various assumptions. Nonetheless, actual results may differ from management's estimates. For a complete summary of our significant accounting policies, please refer to Note 2, "Use of Estimates and Summary of Significant Accounting Policies", in Part II, Item 8, of our 2014 Annual Report on Form 10-K for the year ended December 31, 2014 , filed March 2, 2015. There have been no material changes to our significant accounting policies during the three and six months ended June 30, 2015 .

Balance Sheet Account Detail

Balance Sheet Account Detail	6 Months Ended
	Jun. 30, 2015
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Account Detail	Balance Sheet Account Detail (a) Property and Equipment Property and equipment consisted of the following: June 30, December 31, Production equipment, molds, and office furniture $ 14,054 $ 12,943 Computer hardware and software 7,075 6,457 Leasehold improvements 16,368 15,729 Construction in progress (software and related implementation, production equipment, and leasehold improvements) 573 2,564 Property and equipment, at cost $ 38,070 $ 37,693 Accumulated depreciation (13,262 ) (11,997 ) Property and equipment, net $ 24,808 $ 25,696 Depreciation expense for property and equipment for the three months ended June 30, 2015 and 2014 was $1.1 million and $0.5 million , respectively. For the six months ended June 30, 2015 and 2014 depreciation expense for property and equipment was $2.2 million and $1.0 million , respectively. (b) Inventories Inventories consisted of the following: June 30, December 31, Raw materials $ 5,973 $ 6,728 Work-in-process 8,883 5,946 Finished goods 15,732 18,651 Total Inventories $ 30,588 $ 31,325 (c) Goodwill and Intangible Assets The following table presents goodwill, indefinite lived intangible assets, finite lived intangible assets and related accumulated amortization: June 30, December 31, Goodwill (1) $ 28,709 $ 28,866 Intangible assets: Indefinite lived intangibles Trademarks and trade names $ 2,708 $ 2,708 Finite lived intangibles Developed technology (2) $ 40,100 $ 40,100 Accumulated amortization (454 ) (285 ) Developed technology, net $ 39,646 $ 39,815 License $ 100 $ 100 Accumulated amortization (85 ) (71 ) License, net $ 15 $ 29 Customer relationships (1) $ 438 $ 480 Accumulated amortization (1) (438 ) (400 ) Customer relationships, net $ — $ 80 Acquired Shonin approval (3) $ 1,000 $ 1,000 Accumulated amortization (667 ) (167 ) Acquired Shonin approval, net $ 333 $ 833 Intangible assets (excluding goodwill), net $ 42,702 $ 43,465 (1) Difference in the value between these dates is solely due to a foreign currency translation adjustment. (2) Was reclassified in the first quarter of 2013 from in-process research and development to finite lived intangibles, which coincided with the European commercial launch of the product (Nellix EVAS System) associated with this intangible asset. A significant portion of this intangible asset will not begin amortization until the U.S. launch of this product, currently scheduled for 2016. (3) Regulatory approval for Intuitrak in Japan acquired through an amendment with a distributor in the fourth quarter of 2014. Amortization expense for intangible assets for the three months ended June 30, 2015 and 2014 was $0.4 million and $0.1 million , respectively. For the six months ended June 30, 2015 and 2014 amortization expense for intangible assets was $0.8 million and $0.2 million , respectively. Estimated amortization expense for the five succeeding years and thereafter (which includes amortization of intangible assets which commenced in February 2013 with the commercial launch of the Nellix System in Europe) is as follows: Remainder of 2015 $ 517 2016 949 2017 2,213 2018 3,693 2019 4,750 2020 5,416 2021 & Thereafter 22,456 Total $ 39,994 (d) Marketable securities Investments in held-to-maturity marketable securities consist of the following at June 30, 2015 and December 31, 2014 : June 30, 2015 Amortized Gross Gross Fair Value Asset backed securities $ 857 $ — $ — $ 857 Agency bonds 3,000 — — 3,000 Corporate bonds 2,658 — (1 ) 2,657 Commercial paper 22,781 5 (1 ) 22,785 Government securities 4,961 2 — 4,963 Total $ 34,257 $ 7 $ (2 ) $ 34,262 December 31, 2014 Amortized Gross Gross Fair Value Asset backed securities $ 3,633 $ — $ — $ 3,633 Corporate bonds 15,707 — (8 ) 15,699 Commercial paper 40,531 5 — 40,536 Total $ 59,871 $ 5 $ (8 ) $ 59,868 At June 30, 2015 , the Company’s investments included 6 held-to-maturity debt securities in unrealized loss positions with a total unrealized loss of approximately $2 thousand and a total fair market value of approximately $4.7 million . All investments with gross unrealized losses have been in unrealized loss positions for less than 4 months. The unrealized losses were caused by interest rate fluctuations. There was no change in the credit risk of the securities. The Company does not intend to sell the securities and it is not likely that the Company will be required to sell the securities before the expected recovery of their amortized cost bases. There were no realized gains or losses on the investments for the three and six months ended June 30, 2015 . All of the Company's investments of held-to-maturity securities will mature within less than 12 months with an average maturity of 3 months. (e) Fair Value Measurements The following fair value hierarchy table presents information about each major category of the Company’s assets and liabilities measured at fair value on a recurring basis as of June 30, 2015 and December 31, 2014 : Fair value measurement at reporting date using: Quoted prices in Significant other Significant Total At June 30, 2015 Cash and cash equivalents $ 36,269 $ — $ — $ 36,269 Contingently issuable common stock $ — $ — $ 14,800 $ 14,800 At December 31, 2014 Cash and cash equivalents $ 26,798 $ — $ — $ 26,798 Contingently issuable common stock $ — $ — $ 14,600 $ 14,600 There were no re-measurements to fair value during the three months ended June 30, 2015 of financial assets and liabilities that are not measured at fair value on a recurring basis. There were no transfers between Level 1, Level 2 or Level 3 securities during the three months ended June 30, 2015 . (f) Financial Instruments Not Recorded at Fair Value on a Recurring Basis We measure the fair value of our 2.25% Convertible Senior Notes due 2018 ("Senior Notes") carried at amortized cost quarterly for disclosure purposes. The estimated fair value of the Senior Notes is determined by Level 2 inputs and is based primarily on quoted market prices for the same or similar issues. Based on the market prices, the fair value of our long-term debt was $82.8 million as of June 30, 2015 and $84.5 million as of December 31, 2014 . We measure the fair value of our held-to-maturity marketable securities carried at amortized cost quarterly for disclosure purposes. The fair value of marketable securities is determined by Level 2 inputs and is based primarily on quoted market prices for the same or similar instruments.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Stock-Based Compensation The Company classifies stock-based compensation expense in the accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss, based on the department to which the recipient belongs. Stock-based compensation expense included in cost of goods sold and operating expenses during the three and six months ended June 30, 2015 and 2014 , was as follows: Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 Cost of goods sold $ 226 $ 197 $ 474 $ 404 Operating expenses: Research and development 258 185 486 335 Clinical and regulatory affairs 243 365 428 262 Marketing and sales 839 645 1,587 1,194 General and administrative 842 748 1,644 1,558 Total operating expenses $ 2,182 $ 1,943 $ 4,145 $ 3,349 Total $ 2,408 $ 2,140 $ 4,619 $ 3,753

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share Net loss per share was calculated by dividing net loss by the weighted average number of common shares outstanding for the three and six months ended June 30, 2015 and 2014. Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 Net loss $ (13,001 ) $ (8,993 ) $ (24,215 ) $ (3,698 ) Shares used in computing basic and diluted net loss per share 67,615 62,699 67,441 62,403 Basic and diluted net loss per share $ (0.19 ) $ (0.14 ) $ (0.36 ) $ (0.06 ) The following outstanding Company securities, using the treasury stock method, were excluded from the above calculations of net loss per share because their impact would have been anti-dilutive: Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 Common stock options 1,812 1,813 1,812 1,917 Restricted stock awards 139 420 137 422 Restricted stock units 269 143 257 202 Total 2,220 2,376 2,206 2,541 As discussed in Note 6, in December 2013, the Company issued $86.3 million aggregate principal amount of 2.25% convertible senior notes due 2018 (the “Senior Notes”) in an underwritten public offering. Upon any conversion, the Senior Notes may be settled, at the Company’s election, in cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock. For purposes of calculating the maximum dilutive impact, it is presumed that the Senior Notes will be settled in common stock with the resulting potential common shares included in diluted earnings per share if the effect is more dilutive. The effect of the conversion of the Senior Notes is excluded from the calculation of diluted loss per share because the impact of these securities would be anti-dilutive. The potential dilutive effect of these securities is shown in the chart below: Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 Conversion of the Notes 3,588 3,588 3,588 3,588 The effect of the contingently issuable common stock is excluded from the calculation of basic net loss per share until all necessary conditions for issuance have been satisfied. Refer to Note 9 of the Notes to the Condensed Consolidated Financial Statements for further discussion.

Credit Facilities

Credit Facilities	6 Months Ended
	Jun. 30, 2015
Line of Credit Facility [Abstract]
Credit Facilities	Credit Facilities 2.25% Convertible Senior Notes On December 10, 2013, the Company issued $86.3 million aggregate principal amount 2.25% Convertible Senior Notes (the “Senior Notes”). The Senior Notes mature on December 15, 2018 unless earlier repurchased by the Company or converted. The Company received net proceeds of the Notes of approximately $82.6 million from the sale of the Senior Notes, after deducting underwriting discounts and commissions and offering expenses payable by the Company. Interest is payable on the Senior Notes on June 15 and December 15 of each year, beginning June 15, 2014. The Senior Notes are governed by the terms of a base indenture (the “Base Indenture”), as supplemented by the first supplemental indenture relating to the Senior Notes (the “First Supplemental Indenture,” and together with the Base Indenture, the “Indenture”), between the Company and Wells Fargo Bank, National Association (the “Trustee”), each of which were entered into on December 10, 2013. The Senior Notes are senior unsecured obligations and are (a) senior in right of payment to the Company’s future indebtedness that is expressly subordinated in right of payment to the Senior Notes; (b) equal in right of payment to the Company’s existing and future unsecured indebtedness that is not so subordinated; (c) effectively junior to any of the Company’s secured indebtedness to the extent of the value of the assets securing such indebtedness; (d) and structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company’s subsidiaries. The Company may not redeem the Senior Notes prior to December 15, 2016. On or after December 15, 2016, the Company may redeem for cash all or any portion of the Senior Notes, at its option, but only if the closing sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the second trading day immediately preceding the date on which the Company provides notice of redemption, exceeds 130% of the conversion price on each applicable trading day. The redemption price will equal 100% of the principal amount of the Senior Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the Senior Notes. Holders may convert their Senior Notes at any time prior to the close of business on the business day immediately preceding September 15, 2018 only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2014, if the closing sale price of the Company’s common stock, for at least 20 trading days (whether or not consecutive) in the period of 30 consecutive trading days ending on the last trading day of the calendar quarter immediately preceding the calendar quarter in which the conversion occurs, is more than 130% of the conversion price of the Senior Notes in effect on each applicable trading day; (2) during the five consecutive business-day period following any five consecutive trading-day period in which the trading price for the Senior Notes for each such trading day was less than 98% of the closing sale price of the Company’s common stock on such date multiplied by the then-current conversion rate; (3) if the Company calls all or any portion of the notes for redemption, at any time prior to the close of business on the second scheduled trading day prior to the redemption date; or (4) upon the occurrence of specified corporate events. On or after September 15, 2018 until the close of business on the second scheduled trading day immediately preceding the stated maturity date, holders may surrender their Senior Notes for conversion at any time, regardless of the foregoing circumstances. Upon conversion, the Company will, at its election, pay or deliver, as the case may be, cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock. The initial conversion rate of the Senior Notes will be 41.6051 shares of the Company’s common stock for each $1,000 principal amount of Senior Notes, which represents an initial conversion price of approximately $24.04 per share. Following certain corporate transactions that occur on or prior to the stated maturity date or the Company’s delivery of a notice of redemption, the Company will increase the conversion rate for a holder that elects to convert its Senior Notes in connection with such a corporate transaction. If a fundamental change (as defined in the Indenture) occurs prior to the stated maturity date, holders may require the Company to purchase for cash all or any portion of their Senior Notes at a fundamental change purchase price equal to 100% of the principal amount of the Senior Notes to be purchased, plus accrued and unpaid interest to, but excluding, the fundamental change purchase date. The Indenture contains customary terms and covenants and events of default with respect to the Senior Notes. If an event of default (as defined in the Indenture) occurs and is continuing, either the Trustee or the holders of at least 25% in aggregate principal amount of the outstanding Senior Notes may declare the principal amount of the Senior Notes to be due and payable immediately by notice to the Company (with a copy to the Trustee). If an event of default arising out of certain events of bankruptcy, insolvency or reorganization involving the Company or a significant subsidiary (as set forth in the Indenture) occurs with respect to us, the principal amount of the Senior Notes and accrued and unpaid interest, if any, will automatically become immediately due and payable. The Company was not required to separate the conversion option in the Senior Notes under ASC 815, "Derivatives and Hedging", and has the ability to settle the Senior Notes in cash, common stock or a combination of cash and common stock, at its option. In accordance with cash conversion guidance contained in ASC 470-20, "Debt with Conversion and Other Options", the Company accounted for the Senior Notes by allocating the issuance proceeds between the liability and the equity component. The equity component is classified in stockholders’ equity and the resulting discount on the liability component is accreted such that interest expense equals the Company’s nonconvertible debt borrowing rate. The separation was performed by first determining the fair value of a similar debt that does not have an associated equity component. That amount was then deducted from the initial proceeds of the Senior Notes as a whole to arrive at a residual amount, which was allocated to the conversion feature that is classified as equity. The initial fair value of the indebtedness was $66.9 million resulting in a $19.3 million allocation to the embedded conversion option. The embedded conversion option was recorded in stockholders’ equity and as debt discount, to be subsequently accreted to interest expense over the term of the Senior Notes. Underwriting discounts and commissions and offering expenses totaled $3.7 million and were allocated between the liability and the equity component in proportion to the allocation of proceeds and accounted for as debt issuance costs and equity issuance costs, respectively. As a result, $2.9 million attributable to the indebtedness was recorded as deferred financing costs in other assets, to be subsequently amortized as interest expense over the term of the Senior Notes, and $0.8 million attributable to the equity component was recorded as a reduction to additional paid-in-capital in stockholders’ equity. As of June 30, 2015 , the Company had outstanding borrowings of $72.2 million , and deferred financing costs of $2.2 million , related to the Senior Notes. There are no principal payments due during the term. Annual interest expense on these notes will range from $5.7 million to $6.9 million through maturity. Capped Call Transactions On December 10, 2013, in connection with the pricing of the Senior Notes and the exercise in full of their overallotment option by the underwriters, the Company entered into privately-negotiated capped call transactions (the “Capped Call Transactions”) with Bank of America, N.A., an affiliate of Merrill Lynch, Pierce, Fenner & Smith Incorporated. The Capped Call Transactions initial conversion rate and number of options substantially corresponds to each $1,000 principal amount of Senior Notes. The Company used approximately $7.4 million of the net proceeds from the Senior Notes offering to pay for the cost of the Capped Call Transactions. The Capped Call Transactions are separate transactions entered into by the Company with Bank of America, N.A., are not part of the terms of the Senior Notes and will not change the holders’ rights under the Senior Notes. The Capped Call Transactions have anti-dilution adjustments substantially similar to those applicable to the Senior Notes. The Capped Call Transactions are derivative instruments that are recorded within stockholders’ equity because they meet an exemption from mark-to-market derivative accounting. The Capped Call Transactions are expected generally to reduce the potential dilution and/or offset potential cash payments that the Company is required to make in excess of the principal amount upon conversion of the Senior Notes in the event that the market price per share of the Company’s common stock, as measured under the terms of the Capped Call Transactions, is greater than the strike price of the Capped Call Transactions, which initially corresponds to the $24.04 conversion price of the Senior Notes. If, however, the market price per share of the Company’s common stock, as measured under the terms of the Capped Call Transactions, exceeds the initial cap price of $29.02 , there would nevertheless be dilution and/or there would not be an offset of such potential cash payments, in each case, to the extent that such market price exceeds the cap price of the Capped Call Transactions. The Company will not be required to make any cash payments to Bank of America, N.A. or any of its affiliates upon the exercise of the options that are a part of the Capped Call Transactions, but will be entitled to receive from Bank of America, N.A. (or an affiliate thereof) a number of shares of the Company’s common stock and/or an amount of cash generally based on the amount by which the market price per share of the Company’s common stock, as measured under the terms of the Capped Call Transactions, is greater than the strike price of the Capped Call Transactions during the relevant valuation period under the Capped Call Transactions. However, if the market price of the Company’s common stock, as measured under the terms of the Capped Call Transactions, exceeds the cap price of the Capped Call Transactions during such valuation period under the Capped Call Transactions, the number of shares of common stock and/or the amount of cash the Company expects to receive upon exercise of the Capped Call Transactions will be capped based on the amount by which the cap price exceeds the strike price of the Capped Call Transactions. For any conversions of Senior Notes prior to the close of business on the 55th scheduled trading day immediately preceding the stated maturity date of the Senior Notes, including without limitation upon an acquisition of the Company or similar business combination, a corresponding portion of the Capped Call Transactions will be terminated. Upon such termination, the portion of the Capped Call Transactions being terminated will be settled at fair value (subject to certain limitations), as determined by Bank of America, N.A., in its capacity as calculation agent under the Capped Call Transactions, which the Company expects to receive from Bank of America, N.A., and no payments will be due Bank of America, N.A. The capped call expires on December 13, 2018. Wells Fargo line of credit In October 2009, the Company entered into a revolving credit facility with Wells Fargo Bank (“Wells”), which was last amended on February 3, 2015, whereby the Company may borrow up to $20.0 million , subject to the calculation and limitation of a borrowing base (the “Wells Credit Facility”). All amounts owing under the Wells Credit Facility will become due and payable upon its expiration on November 15, 2015. A sub-feature in the line of credit allows for the issuance of up to $7.5 million in letters of credit. As of June 30, 2015, the Company had no outstanding letters of credit issued. The Wells Credit Facility is collateralized by all of the Company's assets, except its intellectual property. The Wells Credit Facility contains financial covenants requiring the Company to (i) maintain a minimum current ratio of 2.0 , equal to the quotient of modified current assets to current liabilities, as defined in the Wells Credit Facility (the "Current Ratio Covenant"), and (ii) not to exceed pre-tax net loss (excluding non-cash contingent consideration associated with the acquisition of Nellix) of $13.5 million for the three months ended March 31, 2015; $23.0 million for the six months ended June 30, 2015; and $35.0 million for the nine months ended September 30, 2015; (the "Net Loss Covenant"). The Wells Credit Facility also includes negative covenants limiting capital expenditures in 2015 to an aggregate of $6.0 million as well as limiting operating lease expenses to $3.0 million in any calendar year. As of June 30, 2015, the Company was not in compliance with the Net Loss Covenant. The financial covenants as of and for the three and six months ended June 30, 2015 are no longer applicable due to the termination of the Wells Credit Facility on July 21, 2015. The Wells Credit Facility also contains a “material adverse change” clause (“MAC”). If the Company encounters difficulties that would qualify as a MAC in its (i) operations, (ii) condition (financial or otherwise), or (iii) ability to repay amounts outstanding under the Wells Credit Facility, it could be canceled at Wells' sole discretion. Wells could then elect to declare the indebtedness, together with accrued interest and other fees, to be immediately due and payable and proceed against any collateral securing such indebtedness. No borrowings were outstanding at June 30, 2015 and 2014. On July 21, 2015, the Company terminated the credit facility. As of the termination date, the Company had no outstanding borrowings or letters of credits issued under the Wells Credit Facility. Bank of America line of credit O n July 21, 2015 , the Company entered into a revolving credit facility with Bank of America, N.A. (“BOA”), whereby the Company may borrow up to $20.0 million (the “BOA Credit Facility”). All amounts owing under the BOA Credit Facility will become due and payable upon its expiration on July 21, 2017 . A sub-feature in the line of credit allows for the issuance of up to $10.0 million in letters of credit. The BOA Credit Facility is collateralized by all of the Company's assets, except its intellectual property. The BOA Credit Facility can be terminated at any time during the two years by Company upon three business day notice. The BOA Credit Facility usage is priced at a spread over the one, two, three and six month LIBOR rates, and is subject to a covenants related to timely providing of publicly reported information, other indebtedness and a liquidity covenant tied to “Unencumbered Liquid Assets” ("ULA") - (as defined here) of not less than $30.0 million . ULA means the following assets (excluding assets of any retirement plan) which (i) are held in the United States at BOA and/or its affiliates, (ii) are not the subject of any lien, pledge, security interest or other arrangement with any creditor (other than BOA or one of BOA’s affiliates) to have his claim satisfied out of the asset (or proceeds thereof) prior to the general creditors of the owner of the asset, (iii) are held solely in the name of one or more credit parties subject to this covenant (with no other persons or entities having ownership rights therein), (iv) may be converted to cash within five (5) days, and (v) are not being counted or included to satisfy any other liquidity requirement under any other obligation, whether with BOA or any other lender, unless otherwise expressly agreed by BOA in writing: (a) cash and cash equivalents; (b) marketable securities invested in accordance with the Company’s investment policy and (c) marketable securities invested in accordance with any update to the Company’s investment policy so long as such update been approved by BOA in its reasonable discretion. If not in default, the Company has the ability to reduce the ULA covenant requirement by reducing the BOA Credit Facility, with the ULA maintained at 1.5 times the BOA Credit Facility.

Revenue by Geographic Region

Revenue by Geographic Region	6 Months Ended
	Jun. 30, 2015
Geographic Areas, Revenues from External Customers [Abstract]
Revenue by Geographic Region	Revenue by Geographic Region The Company's revenue by geographic region, was as follows: Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 United States $ 28,776 72.9% $ 27,992 73.0% $ 53,910 70.8% $ 51,980 72.6% Europe $ 7,888 20.0% $ 7,816 20.4% $ 15,134 19.9% $ 14,401 20.1% Rest of World ("ROW"): Latin America $ 1,221 3.1% $ 1,309 3.4% $ 3,260 4.3% $ 2,226 3.1% Asia/Pacific 1,594 4.0% 1,210 3.2% 3,845 5.0% 2,984 4.2% Total ROW $ 2,815 7.1% $ 2,519 6.6% $ 7,105 9.3% $ 5,210 7.3% Revenue $ 39,479 100.0% $ 38,327 100.0% $ 76,149 100.0% $ 71,591 100.0%

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies (a) Leases The Company leases its administrative, research, and manufacturing facilities located in Irvine, California and an administrative office located in Rosmalen, The Netherlands. These facility lease agreements require the Company to pay operating costs, including property taxes, insurance and maintenance. In addition, the Company has certain equipment under long-term agreements that are accounted for as operating leases. Future minimum payments by year under non-cancelable leases with initial terms in excess of one year were as follows as of June 30, 2015 : Remainder of 2015 $ 1,271 2016 2,363 2017 2,331 2018 2,258 2019 2,296 2020 2,388 2021 and thereafter 22,884 Total $ 35,791 Facilities rent expense for the three months ended June 30, 2015 and 2014 was $0.6 million and $0.7 million , respectively. For the six months ended June 30, 2015 and 2014 facilities rent expense was $1.2 million and $1.3 million , respectively. On June 12, 2013, the Company entered into a lease agreement for two adjacent office, research and development, and manufacturing facilities in Irvine, California. The premises consist of approximately 129,000 combined square feet. The lease has a 15 -year term beginning January 1, 2014 and provides for one optional five year extension. The initial base rent under the lease is $1.9 million per year, payable in monthly installments, and escalates by 3% per year for years 2015 through 2019, and 4% per year for years 2020 and beyond. The Company received a rent abatement for the first nine months of the lease. These premises replaced the Company's existing Irvine facilities. The terms of this lease agreement provide for $6.8 million of landlord-funded improvements (and certain other allowances) to this facility, in order to best suit the Company's requirements. The Company leased two adjacent facilities aggregating approximately 57,000 square feet in Irvine, California, under separate lease agreements where manufacturing was held. The Company exited one of these leases in December 2014 and the other lease in April 2015. The Company's Rosmalen facility is an administrative office of approximately 2,900 square feet with lease expiration in December 2015 and renewal at its option. (b) Employment Agreements and Retention Plan On February 1, 2014, the Company entered into new employment agreements with certain of its executive officers under which payment and benefits would become payable in the event of termination by the Company for any reason other than cause, death or disability or termination by the employee for good reason (collectively, an “Involuntary Termination”) prior to, upon or following a change in control of the Company. The severance payment will generally be in a range of six to eighteen months of the employee’s then current salary for an Involuntary Termination prior to a change in control of the Company, and will generally be in a range of eighteen to twenty-four months of the employee’s then current salary for an Involuntary Termination upon or following a change in control of the Company. (c) Legal Matters We are from time to time involved in various claims and legal proceedings of a nature we believe are normal and incidental to a medical device business. These matters may include product liability, intellectual property, employment, and other general claims. Such cases and claims may raise complex factual and legal issues and are subject to many uncertainties, including, but not limited to, the facts and circumstances of each particular case or claim, the jurisdiction in which each suit is brought, and differences in applicable law. We accrue for contingent liabilities when it is probable that a liability has been incurred and the amount can be reasonably estimated. The accruals are adjusted periodically as assessments change or as additional information becomes available. LifePort Sciences LLC v. Endologix, Inc. On December 28, 2012, LifePort Sciences, LLC ("LifePort") filed a complaint against us in the U.S. District Court, District of Delaware, alleging that certain of our products infringe U.S. Patent Nos. 5,489,295, 6,117,167, 6,302,906, 5,993,481 and 5,676,696, which are alleged to be owned by LifePort. LifePort is seeking an unspecified amount of monetary damages for sale of our products and injunctive relief. We do not believe that we infringe on any of these patents and we intend to vigorously defend against this matter. The case is currently scheduled for trial in April 2016. We do believe, however, that the outcome will not have a material adverse effect on our financial position, results of operations, or cash flows. However, in order to avoid further legal costs and diversion of management resources, it is reasonably possible that we may reach a settlement with LifePort, which could result in a liability. However, we cannot presently estimate the amount, or range, of reasonably possible losses due to the nature of this potential litigation settlement.

Contingently Issuable Common St

Contingently Issuable Common Stock	6 Months Ended
	Jun. 30, 2015
Business Combinations [Abstract]
Contingently Issuable Common Stock	Contingently Issuable Common Stock On October 27, 2010, the Company entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Nepal Acquisition Corporation, a wholly-owned subsidiary of the Company (“Merger Sub”), Nellix, Inc. ("Nellix"), certain of Nellix’s stockholders named therein and Essex Woodlands Health Ventures, Inc., as representative of the former Nellix stockholders. On December 10, 2010 (the “Nellix Closing Date”), the Company completed the merger (the “Merger”) of Merger Sub with and into Nellix pursuant to the terms of the Merger Agreement. The purchase price consisted of 3.2 million shares of the Company's common stock, issuable to the former Nellix stockholders as of the Nellix Closing Date, then representing a value of $ 19.4 million . Under the agreement, additional payments, solely in the form of shares of the Company's common stock (the “Contingent Payment”), could be made upon the achievement of a revenue milestone and a regulatory approval milestone (collectively, the “Nellix Milestones”). Under the merger agreement, the ultimate value of each Contingent Payment would be determined on the date that each Nellix Milestone is achieved. The number of issuable shares would be established using an applicable per share price, which is subject to a ceiling and/or floor, resulting at the closing of the merger in a potential maximum of 10.2 million shares issuable upon the achievement of the Nellix Milestones. As of the Closing Date, the aggregate fair value of the cash Contingent Payment was estimated to be $ 28.2 million . The Merger Agreement provides that, in addition to the shares of common stock of the Company (the “Common Stock”) issued to the former Nellix stockholders at the closing of the Merger, the former Nellix stockholders were entitled to receive shares of the Common Stock if the Company’s sales of a Nellix product (the “Nellix Product”) outside of the United States exceeded $10.0 million within a certain time period following the Company’s receipt of CE mark approval for the Nellix Product (the “OUS Milestone”). The aggregate dollar value of the shares of the Common Stock to be issued upon achievement of the OUS Milestone ranged from a high of $24.0 million , or 6.9 million shares, to a low of $10.0 million , or 1.3 million shares. The price per share of the Common Stock to be issued upon achievement of the OUS Milestone was subject to a floor of $3.50 per share and a ceiling of $7.50 per share. On June 17, 2014, the Company announced its achievement of the OUS Milestone and the issuance of an aggregate of 2.7 million unregistered shares of the Common Stock (the “OUS Milestone Shares”), plus an amount of cash in lieu of fractional shares, to the former Nellix stockholders. The Company offered and sold the OUS Milestone Shares in reliance upon exemptions from registration pursuant to Section 4(2) under the Securities Act of 1933, as amended (the “Securities Act”). The former Nellix stockholders previously gave representations to the Company regarding their investment intent, experience, financial sophistication, access to information regarding the Company and certain other matters to support the Company’s reasonable belief that it could rely upon the foregoing exemptions from registration pursuant to Section 4(2) of the Securities Act. No underwriting discounts or commissions were or will be paid in conjunction with the issuance of the OUS Milestone Shares. The Company previously filed a Registration Statement on Form S-3 (Registration No. 333-171639) (the “Form S-3”) for the purpose of registering for resale shares of the Common Stock issued or issuable pursuant to the Merger Agreement, including the OUS Milestone Shares. The Securities and Exchange Commission declared the Form S-3 effective on January 18, 2011. In addition, if the Company receives approval from the FDA to sell the Nellix Product in the United States (the “PMA Milestone”), the Company will issue additional shares of the Common Stock to the former stockholders of Nellix. The dollar value of the shares of the Common Stock to be issued upon achievement of the PMA Milestone will be equal to $15.0 million (less the dollar value of certain cash payments and other deductions). The price per share of the shares of the Common Stock to be issued upon achievement of the PMA Milestone is subject to a stock price floor of $4.50 per share, but not subject to a stock price ceiling. As of June 30, 2015 the Company's stock price last closed at $15.34 per share. Thus, had the PMA Milestone been achieved on June 30, 2015 the Contingent Payment would have comprised 0.9 million shares (based on the 30-day average closing stock price ending 5 days prior to the announcement), representing a value of $13.8 million . The value of the Contingent Payment is derived using a discounted income approach model, with a range of probabilities and assumptions related to the timing and likelihood of achievement of the PMA Milestone (which include Level 3 inputs - see Note 3(e) and the Company's stock price (Level 1 input) as of the balance sheet date). These varying probabilities and assumptions and changes in the Company's stock price have required fair value adjustments of the Contingent Payment in periods subsequent to the Nellix Closing Date. The Contingent Payment fair value will continue to be evaluated on a quarterly basis until milestone achievement occurs, or until the expiration of the "earn-out period," as defined within the Nellix purchase agreement. Adjustments to the fair value of the Contingent Payment are recognized within other income (expense) in the Condensed Consolidated Statements of Operations and Comprehensive Loss. Fair Value of Contingently Issuable Common Stock December 31, 2014 $ 14,600 Fair Value Adjustment of Contingent Payment for the six months ended June 30, 2015 200 June 30, 2015 $ 14,800

Income Tax Expense

Income Tax Expense	6 Months Ended
	Jun. 30, 2015
Current Income Tax Expense (Benefit), Continuing Operations [Abstract]
Income Tax Expense	Income Tax Expense The Company applied an estimated annual effective tax rate (“ETR”) approach for calculating a tax provision for interim periods. The Company recorded a provision for income taxes of $0.1 million and $0.2 million for the three and six months ended June 30, 2015 , respectively. The Company's ETR was (0.5)% and (0.7)% for the three and six months ended June 30, 2015 , respectively. The Company's ETR for the three and six months ended June 30, 2015 differs from the U.S. federal statutory tax rate of 34% primarily as a result of nondeductible expenses (including the Nellix Contingent Payment), state income taxes, foreign income taxes, and the impact of a full valuation allowance on its deferred tax assets. The Company has evaluated the available evidence supporting the realization of its deferred tax assets, including the amount and timing of future taxable income, and has determined that it is more likely than not that its net deferred tax assets will not be realized in the U.S. and certain foreign jurisdictions. Due to uncertainties surrounding the realization of the deferred tax assets, the Company maintains a full valuation allowance against substantially all deferred tax assets. If/when the Company determines that it will be able to realize some portion or all of its deferred tax assets, an adjustment to its valuation allowance on its deferred tax assets would have the effect of increasing net income in the period(s) such determination is made.

Description of Business, Basi16

Description of Business, Basis of Presentation, and Operating Segment (Policies)	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") and the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). These financial statements include the financial position, results of operations, and cash flows of the Company, including its subsidiaries, all of which are wholly-owned. All inter-company accounts and transactions have been eliminated in consolidation. For the three and six months ended June 30, 2015 and 2014, there were no related party transactions. The interim financial data as of June 30, 2015 is unaudited and is not necessarily indicative of the results for a full year. In the opinion of the Company's management, the interim data includes normal and recurring adjustments necessary for a fair presentation of the Company's financial results for the three and six months ended June 30, 2015 . Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to SEC rules and regulations relating to interim financial statements. The accompanying Condensed Consolidated Financial Statements should be read in conjunction with the Company's audited Consolidated Financial Statements and Notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2014 , filed with the SEC on March 2, 2015.
Operating segment	Operating Segment The Company has one operating and reporting segment that is focused exclusively on the development, manufacture, marketing, and sale of EVAR and EVAS product for the treatment of aortic disorders. For the three and six months ended June 30, 2015 , all of the Company's revenue and related expenses were solely attributable to these activities. Substantially all of the Company's long-lived assets are located in the U.S.

Balance Sheet Account Detail (T

Balance Sheet Account Detail (Tables)	6 Months Ended
	Jun. 30, 2015
Balance Sheet Related Disclosures [Abstract]
Property and Equipment	Property and equipment consisted of the following: June 30, December 31, Production equipment, molds, and office furniture $ 14,054 $ 12,943 Computer hardware and software 7,075 6,457 Leasehold improvements 16,368 15,729 Construction in progress (software and related implementation, production equipment, and leasehold improvements) 573 2,564 Property and equipment, at cost $ 38,070 $ 37,693 Accumulated depreciation (13,262 ) (11,997 ) Property and equipment, net $ 24,808 $ 25,696
Schedule of Inventories	Inventories consisted of the following: June 30, December 31, Raw materials $ 5,973 $ 6,728 Work-in-process 8,883 5,946 Finished goods 15,732 18,651 Total Inventories $ 30,588 $ 31,325
Schedule of Intangible Assets and Goodwill	The following table presents goodwill, indefinite lived intangible assets, finite lived intangible assets and related accumulated amortization: June 30, December 31, Goodwill (1) $ 28,709 $ 28,866 Intangible assets: Indefinite lived intangibles Trademarks and trade names $ 2,708 $ 2,708 Finite lived intangibles Developed technology (2) $ 40,100 $ 40,100 Accumulated amortization (454 ) (285 ) Developed technology, net $ 39,646 $ 39,815 License $ 100 $ 100 Accumulated amortization (85 ) (71 ) License, net $ 15 $ 29 Customer relationships (1) $ 438 $ 480 Accumulated amortization (1) (438 ) (400 ) Customer relationships, net $ — $ 80 Acquired Shonin approval (3) $ 1,000 $ 1,000 Accumulated amortization (667 ) (167 ) Acquired Shonin approval, net $ 333 $ 833 Intangible assets (excluding goodwill), net $ 42,702 $ 43,465 (1) Difference in the value between these dates is solely due to a foreign currency translation adjustment. (2) Was reclassified in the first quarter of 2013 from in-process research and development to finite lived intangibles, which coincided with the European commercial launch of the product (Nellix EVAS System) associated with this intangible asset. A significant portion of this intangible asset will not begin amortization until the U.S. launch of this product, currently scheduled for 2016. (3) Regulatory approval for Intuitrak in Japan acquired through an amendment with a distributor in the fourth quarter of 2014.
Schedule of Expected Amortization Expense	Estimated amortization expense for the five succeeding years and thereafter (which includes amortization of intangible assets which commenced in February 2013 with the commercial launch of the Nellix System in Europe) is as follows: Remainder of 2015 $ 517 2016 949 2017 2,213 2018 3,693 2019 4,750 2020 5,416 2021 & Thereafter 22,456 Total $ 39,994
Marketable Securities	Investments in held-to-maturity marketable securities consist of the following at June 30, 2015 and December 31, 2014 : June 30, 2015 Amortized Gross Gross Fair Value Asset backed securities $ 857 $ — $ — $ 857 Agency bonds 3,000 — — 3,000 Corporate bonds 2,658 — (1 ) 2,657 Commercial paper 22,781 5 (1 ) 22,785 Government securities 4,961 2 — 4,963 Total $ 34,257 $ 7 $ (2 ) $ 34,262 December 31, 2014 Amortized Gross Gross Fair Value Asset backed securities $ 3,633 $ — $ — $ 3,633 Corporate bonds 15,707 — (8 ) 15,699 Commercial paper 40,531 5 — 40,536 Total $ 59,871 $ 5 $ (8 ) $ 59,868
Fair Value Measurements, Recurring and Nonrecurring	The following fair value hierarchy table presents information about each major category of the Company’s assets and liabilities measured at fair value on a recurring basis as of June 30, 2015 and December 31, 2014 : Fair value measurement at reporting date using: Quoted prices in Significant other Significant Total At June 30, 2015 Cash and cash equivalents $ 36,269 $ — $ — $ 36,269 Contingently issuable common stock $ — $ — $ 14,800 $ 14,800 At December 31, 2014 Cash and cash equivalents $ 26,798 $ — $ — $ 26,798 Contingently issuable common stock $ — $ — $ 14,600 $ 14,600

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	Stock-based compensation expense included in cost of goods sold and operating expenses during the three and six months ended June 30, 2015 and 2014 , was as follows: Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 Cost of goods sold $ 226 $ 197 $ 474 $ 404 Operating expenses: Research and development 258 185 486 335 Clinical and regulatory affairs 243 365 428 262 Marketing and sales 839 645 1,587 1,194 General and administrative 842 748 1,644 1,558 Total operating expenses $ 2,182 $ 1,943 $ 4,145 $ 3,349 Total $ 2,408 $ 2,140 $ 4,619 $ 3,753

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 Net loss $ (13,001 ) $ (8,993 ) $ (24,215 ) $ (3,698 ) Shares used in computing basic and diluted net loss per share 67,615 62,699 67,441 62,403 Basic and diluted net loss per share $ (0.19 ) $ (0.14 ) $ (0.36 ) $ (0.06 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following outstanding Company securities, using the treasury stock method, were excluded from the above calculations of net loss per share because their impact would have been anti-dilutive: Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 Common stock options 1,812 1,813 1,812 1,917 Restricted stock awards 139 420 137 422 Restricted stock units 269 143 257 202 Total 2,220 2,376 2,206 2,541 As discussed in Note 6, in December 2013, the Company issued $86.3 million aggregate principal amount of 2.25% convertible senior notes due 2018 (the “Senior Notes”) in an underwritten public offering. Upon any conversion, the Senior Notes may be settled, at the Company’s election, in cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock. For purposes of calculating the maximum dilutive impact, it is presumed that the Senior Notes will be settled in common stock with the resulting potential common shares included in diluted earnings per share if the effect is more dilutive. The effect of the conversion of the Senior Notes is excluded from the calculation of diluted loss per share because the impact of these securities would be anti-dilutive. The potential dilutive effect of these securities is shown in the chart below: Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 Conversion of the Notes 3,588 3,588 3,588 3,588

Revenue by Geographic Region (T

Revenue by Geographic Region (Tables)	6 Months Ended
	Jun. 30, 2015
Geographic Areas, Revenues from External Customers [Abstract]
Revenue by Geographic Region	The Company's revenue by geographic region, was as follows: Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 United States $ 28,776 72.9% $ 27,992 73.0% $ 53,910 70.8% $ 51,980 72.6% Europe $ 7,888 20.0% $ 7,816 20.4% $ 15,134 19.9% $ 14,401 20.1% Rest of World ("ROW"): Latin America $ 1,221 3.1% $ 1,309 3.4% $ 3,260 4.3% $ 2,226 3.1% Asia/Pacific 1,594 4.0% 1,210 3.2% 3,845 5.0% 2,984 4.2% Total ROW $ 2,815 7.1% $ 2,519 6.6% $ 7,105 9.3% $ 5,210 7.3% Revenue $ 39,479 100.0% $ 38,327 100.0% $ 76,149 100.0% $ 71,591 100.0%

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Contractual Obligation, Fiscal Year Maturity Schedule	Future minimum payments by year under non-cancelable leases with initial terms in excess of one year were as follows as of June 30, 2015 : Remainder of 2015 $ 1,271 2016 2,363 2017 2,331 2018 2,258 2019 2,296 2020 2,388 2021 and thereafter 22,884 Total $ 35,791

Contingently Issuable Common 22

Contingently Issuable Common Stock (Tables)	6 Months Ended
	Jun. 30, 2015
Business Combinations [Abstract]
Schedule of Business Acquisitions by Acquisition, Fair Value of Contingent Consideration	Adjustments to the fair value of the Contingent Payment are recognized within other income (expense) in the Condensed Consolidated Statements of Operations and Comprehensive Loss. Fair Value of Contingently Issuable Common Stock December 31, 2014 $ 14,600 Fair Value Adjustment of Contingent Payment for the six months ended June 30, 2015 200 June 30, 2015 $ 14,800

Description of Business, Basi23

Description of Business, Basis of Presentation, and Operating Segment (Details)	6 Months Ended
	Jun. 30, 2015segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating segments	1
Number of reportable segments	1

Balance Sheet Account Detail (P

Balance Sheet Account Detail (Property and Equipment) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	$ 38,070		$ 38,070		$ 37,693
Accumulated depreciation	(13,262)		(13,262)		(11,997)
Property and equipment, net	24,808		24,808		25,696
Depreciation expense	1,100	$ 500	2,200	$ 1,000
Production equipment, molds, and office furniture
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	14,054		14,054		12,943
Computer hardware and software
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	7,075		7,075		6,457
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	16,368		16,368		15,729
Construction in progress (software and related implementation, production equipment, and leasehold improvements)
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	$ 573		$ 573		$ 2,564

Balance Sheet Account Detail (I

Balance Sheet Account Detail (Inventories) (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Balance Sheet Related Disclosures [Abstract]
Raw materials	$ 5,973	$ 6,728
Work-in-process	8,883	5,946
Finished goods	15,732	18,651
Inventories	$ 30,588	$ 31,325

Balance Sheet Account Detail (G

Balance Sheet Account Detail (Goodwill and Intangible Assets) (Details) - USD ($) $ in Thousands		Jun. 30, 2015	Dec. 31, 2014
Goodwill, Finite-lived, and Indefinite-lived Intangible Assets [Line Items]
Goodwill	[1]	$ 28,709	$ 28,866
Total		39,994
Intangible assets (excluding goodwill), net		42,702	43,465
Developed technology
Goodwill, Finite-lived, and Indefinite-lived Intangible Assets [Line Items]
Finite lived intangibles	[2]	40,100	40,100
Accumulated amortization		(454)	(285)
Total		39,646	39,815
License
Goodwill, Finite-lived, and Indefinite-lived Intangible Assets [Line Items]
Finite lived intangibles		100	100
Accumulated amortization		(85)	(71)
Total		15	29
Customer relationships
Goodwill, Finite-lived, and Indefinite-lived Intangible Assets [Line Items]
Finite lived intangibles	[1]	438	480
Accumulated amortization	[1]	(438)	(400)
Total		0	80
Acquired Shonin approval
Goodwill, Finite-lived, and Indefinite-lived Intangible Assets [Line Items]
Finite lived intangibles	[3]	1,000	1,000
Accumulated amortization		(667)	(167)
Total		333	833
Trademarks and trade names
Goodwill, Finite-lived, and Indefinite-lived Intangible Assets [Line Items]
Indefinite lived intangibles		$ 2,708	$ 2,708
[1]	Difference in the value between these dates is solely due to a foreign currency translation adjustment.
[2]	Was reclassified in the first quarter of 2013 from in-process research and development to finite lived intangibles, which coincided with the European commercial launch of the product (Nellix EVAS System) associated with this intangible asset. A significant portion of this intangible asset will not begin amortization until the U.S. launch of this product, currently scheduled for 2016.
[3]	Regulatory approval for Intuitrak in Japan acquired through an amendment with a distributor in the fourth quarter of 2014.

Balance Sheet Account Detail (A

Balance Sheet Account Detail (Amortization) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Balance Sheet Related Disclosures [Abstract]
Amortization expense	$ 400	$ 100	$ 800	$ 200
Remainder of 2015	517		517
2,016	949		949
2,017	2,213		2,213
2,018	3,693		3,693
2,019	4,750		4,750
2,020	5,416		5,416
2021 & Thereafter	22,456		22,456
Total	$ 39,994		$ 39,994

Balance Sheet Account Detail (H

Balance Sheet Account Detail (Held to Maturity Marketable Securities) (Details) $ in Thousands	Jun. 30, 2015USD ($)securities	Dec. 31, 2014USD ($)
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	$ 34,257	$ 59,871
Gross Unrealized Gain	7	5
Gross Unrealized Loss	(2)	(8)
Fair Value	34,262	59,868
Asset backed securities
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	857	3,633
Gross Unrealized Gain	0	0
Gross Unrealized Loss	0	0
Fair Value	857	3,633
Agency bonds
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	3,000
Gross Unrealized Gain	0
Gross Unrealized Loss	0
Fair Value	3,000
Corporate bonds
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	2,658	15,707
Gross Unrealized Gain	0	0
Gross Unrealized Loss	(1)	(8)
Fair Value	2,657	15,699
Commercial paper
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	22,781	40,531
Gross Unrealized Gain	5	5
Gross Unrealized Loss	(1)	0
Fair Value	22,785	$ 40,536
Government securities
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	4,961
Gross Unrealized Gain	2
Gross Unrealized Loss	0
Fair Value	4,963
Corporate debt securities
Schedule of Held-to-maturity Securities [Line Items]
Gross Unrealized Loss	(2)
Fair Value	$ 4,700
Held-to-maturity debt securities held | securities	6

Balance Sheet Account Detail (F

Balance Sheet Account Detail (Fair Value Measurements) (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 36,269	$ 26,798
Contingently issuable common stock	14,800	14,600
Quoted prices in active markets for identical assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	36,269	26,798
Contingently issuable common stock	0	0
Significant other observable inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Contingently issuable common stock	0	0
Significant unobservable inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Contingently issuable common stock	14,800	14,600
2.25 % Convertible Senior Notes due 2018 | Significant other observable inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of long-term debt	$ 82,800	$ 84,500
Convertible Debt | 2.25 % Convertible Senior Notes due 2018 | Significant other observable inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stated interest rate	2.25%

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense	$ 2,408	$ 2,140	$ 4,619	$ 3,753
Cost of goods sold
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense	226	197	474	404
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense	258	185	486	335
Clinical and regulatory affairs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense	243	365	428	262
Marketing and sales
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense	839	645	1,587	1,194
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense	842	748	1,644	1,558
Total operating expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense	$ 2,182	$ 1,943	$ 4,145	$ 3,349

Net Loss Per Share (Details)

Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 10, 2013
Earnings Per Share, Basic and Diluted [Abstract]
Net loss	$ (13,001)	$ (8,993)	$ (24,215)	$ (3,698)
Shares used in computing basic and diluted net loss per share	67,615	62,699	67,441	62,403
Basic and diluted net loss per share	$ (0.19)	$ (0.14)	$ (0.36)	$ (0.06)
Securities Excluded from Calculations of Earnings Per Share Because Impact Would Have Been Anti-Dilutive [Abstract]
Outstanding securities used in calculations	2,220	2,376	2,206	2,541
Convertible notes	$ 72,156		$ 72,156		$ 70,407
Potential Dilutive Effect of Securities [Abstract]
Conversion of the Notes	3,588	3,588	3,588	3,588
Convertible Debt
Securities Excluded from Calculations of Earnings Per Share Because Impact Would Have Been Anti-Dilutive [Abstract]
Convertible notes						$ 86,300
Stated interest rate					2.25%
Common stock options
Securities Excluded from Calculations of Earnings Per Share Because Impact Would Have Been Anti-Dilutive [Abstract]
Outstanding securities used in calculations	1,812	1,813	1,812	1,917
Restricted stock awards
Securities Excluded from Calculations of Earnings Per Share Because Impact Would Have Been Anti-Dilutive [Abstract]
Outstanding securities used in calculations	139	420	137	422
Restricted stock units
Securities Excluded from Calculations of Earnings Per Share Because Impact Would Have Been Anti-Dilutive [Abstract]
Outstanding securities used in calculations	269	143	257	202

Credit Facilities (Details)

Credit Facilities (Details)	Dec. 10, 2013USD ($)$ / shares$ / securities	Dec. 03, 2013USD ($)	Jun. 30, 2015USD ($)$ / shares	Mar. 31, 2015USD ($)	Jun. 30, 2015USD ($)d$ / shares	Sep. 30, 2015USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Line of Credit Facility [Line Items]
Convertible notes			$ 72,156,000		$ 72,156,000			$ 70,407,000
Deferred finance costs, noncurrent, net			2,200,000		2,200,000
Payments of derivative issuance costs	$ 7,400,000
Revolving Credit Facility | Wells Fargo Bank
Line of Credit Facility [Line Items]
Aggregate maximum borrowing capacity		$ 20,000,000
Minimum current ratio		2
Revolving Credit Facility | Wells Fargo Bank | Measurement Period One
Line of Credit Facility [Line Items]
Maximum operating loss				$ 13,500,000
Revolving Credit Facility | Wells Fargo Bank | Measurement Period Two
Line of Credit Facility [Line Items]
Maximum operating loss					23,000,000
Revolving Credit Facility | Bank of America
Line of Credit Facility [Line Items]
Aggregate maximum borrowing capacity			$ 20,000,000		20,000,000
Minimum current ratio			1.5
Letter of Credit | Wells Fargo Bank
Line of Credit Facility [Line Items]
Aggregate maximum borrowing capacity		$ 7,500,000
Letter of Credit | Bank of America
Line of Credit Facility [Line Items]
Aggregate maximum borrowing capacity			$ 10,000,000		$ 10,000,000
Convertible Senior Notes Issued December, 2013 | Convertible Debt
Line of Credit Facility [Line Items]
Debt instrument face amount	86,250,000
Proceeds from convertible debt	$ 82,600,000
Conversion of convertible securities					41.6051
Redemption price percentage					100.00%
Violation or event of default, declaration by note holders, percentage					25.00%
Fair value disclosure			66,900,000		$ 66,900,000
Beneficial conversion feature					19,300,000
Unamortized discount			$ 3,700,000		$ 3,700,000
Convertible conversion price | $ / shares	$ 24.04		$ 24.04		$ 24.04
Cap price | $ / securities	29.02
Redemption, Period One | Convertible Senior Notes Issued December, 2013 | Convertible Debt
Line of Credit Facility [Line Items]
Threshold trading days | d					20
Threshold consecutive trading days					30 days
Threshold percentage of stock price trigger					130.00%
Redemption price percentage					100.00%
Redemption, Period Two | Convertible Senior Notes Issued December, 2013 | Convertible Debt
Line of Credit Facility [Line Items]
Threshold trading days | d					20
Threshold consecutive trading days					30 days
Threshold percentage of stock price trigger					98.00%
Threshold business days | d					5
Threshold consecutive business days					5 years
Other Assets | Convertible Senior Notes Issued December, 2013 | Convertible Debt
Line of Credit Facility [Line Items]
Unamortized discount			$ 2,900,000		$ 2,900,000
Additional Paid-in Capital | Convertible Senior Notes Issued December, 2013 | Convertible Debt
Line of Credit Facility [Line Items]
Unamortized discount			800,000		$ 800,000
Minimum | Revolving Credit Facility | Bank of America
Line of Credit Facility [Line Items]
Credit Derivative, Liquidation Proceeds, Monetary Amount			$ 30,000,000
Forecast | Revolving Credit Facility | Wells Fargo Bank | Measurement Period Three
Line of Credit Facility [Line Items]
Maximum operating loss						$ 35,000,000
Maximum annual capital expenditures							$ 6,000,000
Forecast | Revolving Credit Facility | Wells Fargo Bank | Measurement Period Four
Line of Credit Facility [Line Items]
Maximum annual capital expenditures							3,000,000
Forecast | Minimum | Convertible Senior Notes Issued December, 2013 | Convertible Debt
Line of Credit Facility [Line Items]
Periodic interest payment							5,700,000
Forecast | Maximum | Convertible Senior Notes Issued December, 2013 | Convertible Debt
Line of Credit Facility [Line Items]
Periodic interest payment							$ 6,900,000
Fair Value, Measurements, Recurring | Significant other observable inputs (Level 2) | 2.25 % Convertible Senior Notes due 2018 | Convertible Debt
Line of Credit Facility [Line Items]
Stated interest rate			2.25%		2.25%

Revenue by Geographic Region (D

Revenue by Geographic Region (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Schedule of Revenue by Geographic Region [Line Items]
Revenue	$ 39,479	$ 38,327	$ 76,149	$ 71,591
Geographic Concentration Risk | Sales
Schedule of Revenue by Geographic Region [Line Items]
Revenue	$ 39,479	$ 38,327	$ 76,149	$ 71,591
Concentration risk percentage	100.00%	100.00%	100.00%	100.00%
Geographic Concentration Risk | Sales | United States | Direct
Schedule of Revenue by Geographic Region [Line Items]
Revenue	$ 28,776	$ 27,992	$ 53,910	$ 51,980
Concentration risk percentage	72.90%	73.00%	70.80%	72.60%
Geographic Concentration Risk | Sales | Europe
Schedule of Revenue by Geographic Region [Line Items]
Revenue	$ 7,888	$ 7,816	$ 15,134	$ 14,401
Concentration risk percentage	20.00%	20.40%	19.90%	20.10%
Geographic Concentration Risk | Sales | Rest of World (ROW): | Distributor
Schedule of Revenue by Geographic Region [Line Items]
Revenue	$ 2,815	$ 2,519	$ 7,105	$ 5,210
Concentration risk percentage	7.10%	6.60%	9.30%	7.30%
Geographic Concentration Risk | Sales | Latin America | Distributor
Schedule of Revenue by Geographic Region [Line Items]
Revenue	$ 1,221	$ 1,309	$ 3,260	$ 2,226
Concentration risk percentage	3.10%	3.40%	4.30%	3.10%
Geographic Concentration Risk | Sales | Asia/Pacific | Distributor
Schedule of Revenue by Geographic Region [Line Items]
Revenue	$ 1,594	$ 1,210	$ 3,845	$ 2,984
Concentration risk percentage	4.00%	3.20%	5.00%	4.20%

Commitments and Contingencies34

Commitments and Contingencies (Details) $ in Thousands	Jun. 12, 2013USD ($)ft²optionfacility	Dec. 31, 2014lease	Jun. 30, 2015USD ($)letters_of_credit	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)letters_of_credit	Jun. 30, 2014USD ($)
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
Remainder of 2015			$ 1,271		$ 1,271
2,016			2,363		2,363
2,017			2,331		2,331
2,018			2,258		2,258
2,019			2,296		2,296
2,020			2,388		2,388
2021 and thereafter			22,884		22,884
Total			35,791		35,791
Rent expense			$ 600	$ 700	$ 1,200	$ 1,300
Number of facilities | facility	2
Aggregate square feet | ft²	129,000
Term of contract	15 years
Number of renewal options | option	1
Renewal term	5 years
Initial base rent	$ 1,900
Landlord-funded improvements	$ 6,800
Number of letters of credit | letters_of_credit			2		2
Number of leases exited | lease		1
Operating Leases, Future Minimum Payments Due, Base Rent Increases [Abstract]
2,015	3.00%
2,016	3.00%
2,017	3.00%
2,018	3.00%
2,019	3.00%
2020 and beyond	4.00%
Manufacturing Facility
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
Aggregate square feet | ft²	57,000
Building
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
Aggregate square feet | ft²	2,900

Contingently Issuable Common 35

Contingently Issuable Common Stock (Details) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	Jun. 17, 2014	Dec. 10, 2010	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Jun. 16, 2014
Fair Value of Contingently Issuable Common Stock [Roll Forward]
December 31, 2014					$ 14,600
Fair Value Adjustment of Contingent Payment for the six months ended June 30, 2015			$ 100	$ 3,772	200	$ (8,028)
June 30, 2015			$ 14,800		14,800
Nelix Milestones
Business Acquisition [Line Items]
Number of shares contingently issuable		10.2
Estimated fair value of contingent payment		$ 28,200
OUS Milestone
Business Acquisition [Line Items]
Purchase price common shares	2.7
OUS Milestone | Common Stock
Business Acquisition [Line Items]
Contingent consideration, liability, value, low					$ 10,000
Contingent consideration, liability, shares, low					1.3
Contingent consideration, liability, value, high					$ 24,000
Contingent consideration, liability, shares, high					6.9
OUS Milestone | Common Stock | Minimum
Business Acquisition [Line Items]
Share price							$ 3.50
OUS Milestone | Common Stock | Maximum
Business Acquisition [Line Items]
Share price							$ 7.50
PMA Milestone
Business Acquisition [Line Items]
Common shares value		$ 15,000
Number of shares contingently issuable					0.9
Closing stock price			$ 15.34		$ 15.34
Contingent consideration, at fair value hypothetical value			$ 13,800		$ 13,800
PMA Milestone | Maximum
Business Acquisition [Line Items]
Share price		$ 4.50
Nellix
Business Acquisition [Line Items]
Purchase price common shares		3.2
Common shares value		$ 19,400

Income Tax Expense (Details)

Income Tax Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Current Income Tax Expense (Benefit), Continuing Operations [Abstract]
Income tax (expense) benefit	$ (61)	$ 80	$ (153)	$ (136)
Effective income tax rate	(0.50%)		(0.70%)
Federal statutory income tax rate	34.00%		34.00%